Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 17;9(7):e028577.
doi: 10.1136/bmjopen-2018-028577.

Evaluation of a personalised adherence intervention to improve photoprotection in adults with Xeroderma Pigmentosum (XP): protocol for the trial of XPAND

Jessica Walburn  1 , Sam Norton  2   3 , Robert Sarkany  4 , Kirby Sainsbury  5 , Vera Araújo-Soares  5 , Myfanwy Morgan  1 , Martha Canfield  2 , Lesley Foster  4 , Jakob Heydenreich  6 , Paul McCrone  7 , Adrian Mander  8 , Falko F Sniehotta  5   9 , Hans Christian Wulf  6 , John Weinman  1
Affiliations

Evaluation of a personalised adherence intervention to improve photoprotection in adults with Xeroderma Pigmentosum (XP): protocol for the trial of XPAND

Jessica Walburn et al. BMJ Open. .

Abstract

Introduction: Poor adherence to photoprotection for people with xeroderma pigmentosum (XP) can be life-threatening. A randomised controlled trial (RCT) is being conducted to test the efficacy of a personalised adherence intervention (XPAND) to reduce the level of ultraviolet radiation (UVR) reaching the face, by improving photoprotection activities in adults with XP.

Methods and analysis: A two-armed parallel groups RCT, where we randomised 24 patients with suboptimal adherence to either an intervention group who received XPAND in 2018 or a delayed intervention group who will receive XPAND in 2019. XPAND involves seven sessions, one-to-one with a facilitator, using behaviour change techniques and specially designed materials to target barriers to photoprotection. Following baseline assessment in April 2018 (t0) and intervention, the primary outcome will be measured across 21 consecutive days in June and July 2018 (t1). The primary outcome is the average daily UVR dose to the face (D-to-F), calculated by combining objective UVR exposure at the wrist (measured by a dosimeter) with face photoprotection activities recorded on a daily UVR protection diary. Secondary outcomes include average daily UVR D-to-F across 21 days in August (t2); psychosocial process variables measured by daily questions (t0, t1, t2) and self-report questionnaires (t0, t1, t2, December 2018 (t3)). Intervention cost-utility is assessed by service use and personal cost questionnaires (t0, t3). The delayed intervention control arm participants will complete three further assessments in April 2019 (t4) and June-July 2019 (t5), and December 2019 (t6) with dosimetry and UVR protection diary completed for 21 days at t4 and t5. A process evaluation will be conducted using mixed methods.

Ethics and dissemination: Ethical approval has been received from West London & GTAC REC 17/LO/2110. Results will be disseminated in peer-reviewed journals and at conferences. This study tests a novel intervention, which, if successful, will be integrated into routine care.

Trial registration number: NCT03445052; Pre-results.

Keywords: RCT; adherence; behaviour change; photoprotection; xeroderma pigmentosum.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Progression of participants through the study.
Figure 2
Figure 2
Structure of the XPAND intervention.
See this image and copyright information in PMC

References

    1. Fassihi H, Sethi M, Fawcett H, et al. . Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect. Proc Natl Acad Sci U S A 2016;113:E1236–45. 10.1073/pnas.1519444113 - DOI - PMC - PubMed
    1. Bradford PT, Goldstein AM, Tamura D, et al. . Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011;48:168–76. 10.1136/jmg.2010.083022 - DOI - PMC - PubMed
    1. Sainsbury K, Vieira R, Walburn J, et al. . Understanding and predicting a complex behavior using n-of-1 methods: Photoprotection in xeroderma pigmentosum. Health Psychol 2018;37:1145–58. 10.1037/hea0000673 - DOI - PubMed
    1. Cooper V, Clatworthy J. Adherence research summarised: unique patient challenges and support solutions in rare diseases. 2016. http://www.altantishealthcare.com/.
    1. Walburn J, Sarkany R, Norton S, et al. . An investigation of the predictors of photoprotection and UVR dose to the face in patients with XP: a protocol using observational mixed methods. BMJ Open 2017;7:e018364 10.1136/bmjopen-2017-018364 - DOI - PMC - PubMed

Publication types

Substances

Associated data